Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, October 11, 2023
[ Wed, Oct 11th 2023
] - WOPRAI
[ Wed, Oct 11th 2023
] - WOPRAI
[ Wed, Oct 11th 2023
] - WOPRAI
[ Wed, Oct 11th 2023
] - WOPRAI
[ Wed, Oct 11th 2023
] - WOPRAI
[ Wed, Oct 11th 2023
] - WOPRAI
[ Wed, Oct 11th 2023
] - WOPRAI
[ Wed, Oct 11th 2023
] - WOPRAI
[ Wed, Oct 11th 2023
] - WOPRAI
[ Wed, Oct 11th 2023
] - WOPRAI
[ Wed, Oct 11th 2023
] - WOPRAI
[ Wed, Oct 11th 2023
] - WOPRAI
[ Wed, Oct 11th 2023
] - WOPRAI
[ Wed, Oct 11th 2023
] - WOPRAI
[ Wed, Oct 11th 2023
] - WOPRAI
[ Wed, Oct 11th 2023
] - WOPRAI
[ Wed, Oct 11th 2023
] - WOPRAI
[ Wed, Oct 11th 2023
] - WOPRAI
[ Wed, Oct 11th 2023
] - WOPRAI
[ Wed, Oct 11th 2023
] - WOPRAI
[ Wed, Oct 11th 2023
] - WOPRAI
[ Wed, Oct 11th 2023
] - WOPRAI
[ Wed, Oct 11th 2023
] - WOPRAI
[ Wed, Oct 11th 2023
] - WOPRAI
[ Wed, Oct 11th 2023
] - WOPRAI
[ Wed, Oct 11th 2023
] - WOPRAI
[ Wed, Oct 11th 2023
] - WOPRAI
[ Wed, Oct 11th 2023
] - WOPRAI
[ Wed, Oct 11th 2023
] - WOPRAI
Michael Ulz Maintained (AKRO) at Buy with Decreased Target to $33 on, Oct 11th, 2023
Michael Ulz of Morgan Stanley, Maintained "Akero Therapeutics, Inc." (AKRO) at Buy with Decreased Target from $70 to $33 on, Oct 11th, 2023.
Michael has made no other calls on AKRO in the last 4 months.
There are 2 other peers that have a rating on AKRO. Out of the 2 peers that are also analyzing AKRO, 0 agree with Michael's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Michael
- Liisa Bayko of "Evercore ISI Group" Maintained at Buy with Increased Target to $60 on, Wednesday, September 13th, 2023
- Eliana Merle of "UBS" Initiated at Strong Buy and Held Target at $83 on, Monday, August 28th, 2023
